Anti-inflammatory Patents (Class 514/18.7)
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Publication number: 20140056906Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: October 8, 2013Publication date: February 27, 2014Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
-
Publication number: 20140051639Abstract: Compositions and methods for the treatment of asthma and inflammatory ocular disorders are disclosed.Type: ApplicationFiled: October 29, 2013Publication date: February 20, 2014Applicant: The Children's Hospital of PhiladelphiaInventor: Michael M. Grunstein
-
Publication number: 20140050739Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Patent number: 8653032Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: GrantFiled: November 8, 2010Date of Patent: February 18, 2014Assignees: Korea Food Research Institute, SNU R & DB FoundationInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Publication number: 20140045756Abstract: The present disclosure relates to methods and compositions for modulating TNF and TNFR signaling. In particular, the disclosure describes methods and compositions for inhibiting TNF? signaling, such as in the prevention or treatment of TNF?-related diseases.Type: ApplicationFiled: March 9, 2012Publication date: February 13, 2014Applicant: New York UniversityInventor: Chuan-Ju Liu
-
Patent number: 8642041Abstract: The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.Type: GrantFiled: March 21, 2010Date of Patent: February 4, 2014Assignee: Protab Ltd.Inventors: Yaakov Naparstek, Eli Moallem
-
Publication number: 20130336948Abstract: A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Applicant: Restorsea, LLCInventors: Enrique P. Alabata, Patricia S. Pao
-
Publication number: 20130331310Abstract: This invention describes an ICE inhibitor prodrug (I) having good bioavailability. Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.Type: ApplicationFiled: December 10, 2012Publication date: December 12, 2013Inventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8603489Abstract: The invention refers to compositions that comprise the protein preparation, obtained from the latex of Hevea brasiliensis, in a low concentration. Additionally, the invention refers to the use of the protein preparation or the composition described herein, for the preparation of a medicine to treat chronic inflammatory diseases, and to the method of treating same that uses the aforementioned composition or the protein preparation.Type: GrantFiled: June 26, 2009Date of Patent: December 10, 2013Assignee: Pele Nova Biotecnologia S.A.Inventor: Fatima Mrue
-
Publication number: 20130316957Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20130316955Abstract: The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and/or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.Type: ApplicationFiled: January 9, 2012Publication date: November 28, 2013Applicant: MERCK PATENT GMBHInventors: Markus Klein, Christos Tsaklakidis, Hans Guehring, Brigitta Leuthner
-
Patent number: 8592375Abstract: This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biological functions and one or more corresponding activator sites that can each initiate or amplify the biological function of one or more effectors upon context-activation. The context-activated protides of the invention are useful in the diagnosis, prophylaxis, and therapy of a broad range of pathological conditions.Type: GrantFiled: August 20, 2003Date of Patent: November 26, 2013Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Michael R. Yeaman, Nannette Y. Yount, John E. Edwards, Jr., Eric P. Brass
-
Publication number: 20130310320Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.Type: ApplicationFiled: January 11, 2013Publication date: November 21, 2013Applicant: Millennium Pharmaceuticals, Inc.Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
-
Publication number: 20130310309Abstract: A topical pharmaceutical composition for treating a skin disorder selected from the group consisting of Herpes viral infection, Varicella viral infection, rash, insect bites, jellyfish stings, burns, psoriasis, itching, skin allergic response, skin lesions as a result of drug or medical treatment side effects or complications, and hypopigmantation. The composition comprises a peptide of the formula pGLU-X—Y—Z, where X, Y and Z are amino acids, with or without an alkyl group, and a pharmaceutically acceptable excipient.Type: ApplicationFiled: March 25, 2012Publication date: November 21, 2013Applicant: S.I.S. Shulov Innovative Science Ltd.Inventor: Naftali Primor
-
Patent number: 8580743Abstract: A recombinant galectin 9 (rGal 9) is provided which exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response.Type: GrantFiled: August 22, 2012Date of Patent: November 12, 2013Assignee: Galpharma Co., Ltd.Inventors: Nozomu Nishi, Mitsuomi Hirashima, Akira Yamauchi, Aiko Ito
-
Patent number: 8580742Abstract: Topical compositions to address menopausal skin conditions comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16-C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.Type: GrantFiled: March 5, 2010Date of Patent: November 12, 2013Assignee: N.V. Perricone LLCInventor: Nicholas V. Perricone
-
Publication number: 20130296224Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators. Exemplary modulators include inhibitors of PKC-alpha, PKC-epsilon and PKC-eta, as well as activators of PKC-delta.Type: ApplicationFiled: January 23, 2013Publication date: November 7, 2013Inventors: Liora BRAIMAN-WIKSMAN, Tamar TENNENBAUM, Yuval SAGIV, Marina GARTSBEIN, Ephraim BRENER, Moshe BEN-HAMO, Liat HAMMER
-
Publication number: 20130296250Abstract: The present disclosure provides a method and kit for treatment of psoriasis using PKC-alpha inhibitors. Exemplary inhibitors include peptide PKC-alpha inhibitors which specifically inhibit PKC-alpha activity leading to the attenuation and treatment of psoriasis.Type: ApplicationFiled: January 16, 2013Publication date: November 7, 2013Inventor: HEALOR LTD.
-
Patent number: 8575089Abstract: The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury.Type: GrantFiled: August 17, 2010Date of Patent: November 5, 2013Assignee: University-Industry Cooperation Group of Kyung HeeInventors: Young Sook Son, Hyun Sook Hong, Do Yeon Kim, Eun Kyung Lee
-
Patent number: 8575106Abstract: Cosmetic compositions comprising a metal-complexed peptide fraction of stressed yeast extracts and/or a calcium influx inhibitor are disclosed, as well as methods of using such compositions to impart exfoliating, anti-aging, anti-lipid, anti-inflammatory, and/or lightening benefits to the skin; and/or lightening benefits to the hair. These compositions are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging, inflammation, lipid synthesis, and melanin production.Type: GrantFiled: August 4, 2010Date of Patent: November 5, 2013Assignee: Avon Products, Inc.Inventors: Uma Santhanam, Christos D. Kyrou, Desiree Mazich, Qi Hong, Hussam H. Shaheen
-
Publication number: 20130274187Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.Type: ApplicationFiled: June 24, 2013Publication date: October 17, 2013Inventors: Soren Mogelsvang, Cohava Gelber
-
Publication number: 20130274196Abstract: The present disclosure provides a method, composition and kit for treatment of inflammatory disease and disorder using PKC isoform modulators.Type: ApplicationFiled: December 10, 2012Publication date: October 17, 2013Inventors: Liora BRAIMAN-WIKSMAN, Tamar TENNENBAUM, Yuval SAGIV, Marina GARTSBEIN, Ephraim BRENER, Moshe BEN-HAMO, Liat HAMMER
-
Patent number: 8551950Abstract: A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (AT2 receptor) antagonists is disclosed. The AT2 receptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.Type: GrantFiled: March 20, 2007Date of Patent: October 8, 2013Assignee: Spinifex Pharmaceuticals Pty LtdInventor: Maree Therese Smith
-
Patent number: 8546340Abstract: A soothing cosmetic or pharmaceutical composition that includes at least one peptide that activates human HMG-CoA reductase general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AAp-R2 in a physiologically suitable medium is disclosed. The invention further applies to a cosmetic treatment method intended to combat skin irritations. Additionally, methods of treating skin irritations with such a composition are described.Type: GrantFiled: December 23, 2009Date of Patent: October 1, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8545851Abstract: The present invention relates to a composition for improving inflammatory disease, and more specifically to a composition for improving inflammatory disease able to improve inflammatory reactions and the barrier function of epithelial tissue such as the skin, to enhance aging resistance and skin elasticity and to prevent or treat aging.Type: GrantFiled: January 7, 2010Date of Patent: October 1, 2013Assignee: SNU R&DB FoundationInventors: Jang Hee Oh, Ji-Yong Jung, Dong Hun Lee, Serah Lee, Yeon Kyung Kim, Jeong-eun Shin, June Hyunkyung Lee, Jin Ho Chung
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Publication number: 20130236509Abstract: The invention relates to a biodegradable microparticle having a diameter between 0.2 and 3.5 micrometer and comprising a pharmaceutically effective amount of at least one small heat-shock protein that induces IL-10 production in macrophages, said small heat-shock protein comprising an amino acid sequence identity of at least 50% to any of the sequences listed as SEQ ID NOs: 1 and 12-26.Type: ApplicationFiled: July 14, 2011Publication date: September 12, 2013Applicant: DELTA CRYSTALLON B.V.Inventor: Johannes Maria Van Noort
-
Publication number: 20130237484Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.Type: ApplicationFiled: April 25, 2011Publication date: September 12, 2013Applicants: Nanao Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University R&DB FoundationInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
-
Patent number: 8530406Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-Gly-Glu-Leu-Ser-X2-X3-(AA)p-R2, derived from human HMG-CoA reductase. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.Type: GrantFiled: December 23, 2009Date of Patent: September 10, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8524666Abstract: The invention relates to a method of treatment for states related to inhibition of angiogenesis and endothelial cell proliferation comprising administering an effective amount of vimentin or its derivatives or its fragments, to a subject in need thereof. Further, the invention relates to a pharmaceutical composition and a medicament comprising vimentin, as well as the use of vimentin in the manufacture of a medicament. Hereby, angiogenesis and endothelial cell proliferation can be controlled, and therapeutic treatment for related states is provided.Type: GrantFiled: July 4, 2008Date of Patent: September 3, 2013Assignee: IBCC Holding ASInventors: Taavi Pall, Wally Anderson, Lagle Kasak, Anne Pink, Priit Kogerman, Aire Allikas, Andres Valkna
-
Publication number: 20130225479Abstract: The present invention provides methods and compositions for treating inflammation and inflammatory disorders in a subject, by administering an effective amount of KSHV-Orf63 and/or active peptides and/or fragments thereof.Type: ApplicationFiled: August 26, 2011Publication date: August 29, 2013Applicant: The University of North Carolina at Chapel HillInventors: Blossom Damania, Jenny P.-Y. Ting, Sean Gregory
-
Publication number: 20130210741Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.Type: ApplicationFiled: January 29, 2013Publication date: August 15, 2013Applicant: 13 THERAPEUTICS, INC.Inventor: 13 Therapeutics, Inc.
-
Publication number: 20130203679Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.Type: ApplicationFiled: January 29, 2013Publication date: August 8, 2013Applicant: 13 THERAPEUTICS, INC.Inventor: 13 Therapeutics, Inc.
-
Patent number: 8501677Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.Type: GrantFiled: October 28, 2011Date of Patent: August 6, 2013Assignee: University of North Carolina at Chapel HillInventors: Jenny P.-Y. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
-
Patent number: 8496935Abstract: The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.Type: GrantFiled: March 16, 2011Date of Patent: July 30, 2013Assignee: Perseid Therapeutics LLCInventors: Erik E Karrer, Madan M. Paidhungat, Steven H Bass, Margaret Neighbors, Juha Punnonen, Steven J. Chapin
-
Patent number: 8491899Abstract: The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.Type: GrantFiled: March 10, 2011Date of Patent: July 23, 2013Assignee: Perseid Therapeutics LLCInventors: Erik E Karrer, Madan M. Paidhungat, Steven H Bass, Margaret Neighbors, Juha Punnonen, Steven J. Chapin
-
Patent number: 8481495Abstract: The present invention describes compounds of the formula pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: GrantFiled: May 25, 2010Date of Patent: July 9, 2013Assignee: TetraLogic Pharmaceuticals CorporationInventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
-
Publication number: 20130164306Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: ApplicationFiled: November 15, 2012Publication date: June 27, 2013Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: SANFORD-BURNHAM MEDICAL RESEARCH IN
-
Publication number: 20130164303Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: November 7, 2011Publication date: June 27, 2013Applicant: Orthogen AGInventors: Peter Wehling, Julio Reinecke
-
Publication number: 20130156729Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.Type: ApplicationFiled: February 7, 2013Publication date: June 20, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Patent number: 8460697Abstract: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.Type: GrantFiled: June 25, 2010Date of Patent: June 11, 2013Assignee: Susavion Biosciences, Inc.Inventors: Laura L. Eggink, J. Kenneth Hoober
-
Patent number: 8460647Abstract: The invention provides isolated Pre-Ligand Assembly Domain (PLAD) polypeptides comprising an amino acid sequence of a domain (e.g., a Fibronectin Ill-like domain) of an IL-17 Receptor (IL-17R) family member, wherein the PLAD polypeptide inhibits multimerization of a receptor complex comprising an IL-17R family member. Also provided are isolated PLAD-binding polypeptides, e.g., antibodies and avimers, which specifically bind to a PLAD polypeptide described herein. Related chimeric proteins, conjugates, nucleic acids, vectors, and host cells are provided herein. Further provided are methods of treating an inflammatory or autoimmune disease, methods of inhibiting IL-17-mediated signal transduction, methods of inhibiting IL-17 ligand binding, methods of inhibiting multimerization of IL-17R complexes, and methods of inhibiting the production of at least one cytokine, chemokine, matrix metalloproteinase, or other molecule associated with IL-17 signal transduction are provided.Type: GrantFiled: April 20, 2008Date of Patent: June 11, 2013Assignees: Amgen Inc., Research Foundation of the State University of New YorkInventors: Sarah L. Gaffen, Fang Shen, Walter Hanel, Jill Kramer, James P. Malone, Michael Wittekind, Raymond Paxton
-
Publication number: 20130122046Abstract: Use of an ubiquitination pathway-related factor, its agonist or antagonist in the preparation of a composition for regulating FOXP3, IL-2, and/or IFN-? activity, in which the ubiquitination pathway-related factor is selected from: Toll-like receptor, ubiquitin ligase, pro-inflammatory cytokine family receptor, and/or its coding sequence. The new type of regulatory factors can regulate regulatory T cells and immune system by regulating FOXP3, IL-2, and/or IFN-? activity. The regulatory factors and their derivatives can also be used as immunoadjuvant for treating or preventing major diseases (such as, infectious diseases and tumor, etc).Type: ApplicationFiled: July 11, 2011Publication date: May 16, 2013Applicant: INSTITUT PASTEUR OF SHANGHAI, CASInventors: Bin Li, Fang Lin, Zuojia Chen, Zhiyuan Li, Fan Pan
-
Patent number: 8440789Abstract: A cosmetic or pharmaceutical composition, and particularly dermatological composition, comprising, in a physiologically adapted medium, as active principle, polypeptides or peptides, and methods of administering a composition capable of increasing cell energy and to protect the skin from oxidative damage. Also, a cosmetic treatment procedure aimed at protecting the skin and the skin appendages from external aggressions and to combat skin aging.Type: GrantFiled: April 23, 2008Date of Patent: May 14, 2013Assignee: Societe d'Extraction des Principes Actifs (Vincience)Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20130115195Abstract: A dietary supplement based on fucoidan, blue-green algae, phycocyanin and phenylethylamine is fortified with one or more of curcumin, silymarin, resveratrol, astragalus root extract, astragoloside IV, vitamin D3, vitamin C, anhydrous trimethylglycine and brewers yeast to stimulate stem cell production and reduce the rate of telomere reduction or shortening. This can result in the repair of existing body cells and enhance longevity by stimulating the production of new stem cells and maintaining the telomeres on new stem cells as well as existing cells. The dietary supplement supports an increased life span by enhancing metabolic function, activating SIRT-1 anti-aging genes, and encouraging the production of new cells with longer telomeres.Type: ApplicationFiled: December 21, 2012Publication date: May 9, 2013Inventor: John V. Cappello
-
Publication number: 20130115167Abstract: The invention provides methods of targeting atherosclerotic plaques using LyP-1 related peptides. The invention additionally provides methods of treating an inflammatory condition using LyP-1 related peptides.Type: ApplicationFiled: June 22, 2012Publication date: May 9, 2013Applicant: Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Juliana Hamzah
-
Publication number: 20130115226Abstract: The present disclosure provides methods and uses of Tie2 binding and/or activating agents. In particular, the present disclosure provides methods and uses for inhibiting the expansion of colony forming unit-granulocytes, reducing eosinophils and/or basophils, for treating allergic disease or response or eosinophil/basophil associated condition and for reducing inflammatory cytokine and/or chemokine levels.Type: ApplicationFiled: April 28, 2011Publication date: May 9, 2013Applicant: Sunnybrook Health Sciences CentreInventors: Paul Van Slyke, Daniel Dumont
-
Patent number: 8435548Abstract: Disclosed are peptide derivatives, wherein glutathione-like peptides are connected to benzoic acid derivatives, and a cosmetic composition comprising the same. The peptide derivatives have excellent tyrosinase inhibition and anti-oxidative activities to show excellent skin whitening effect, biocompatibility without skin stimulation, and stability during long-term storage. Therefore, they can be effectively used for a cosmetic composition for skin whitening.Type: GrantFiled: December 23, 2009Date of Patent: May 7, 2013Assignee: Bio-FD&C Co., LtdInventors: Dai Hyun Jung, Sang Hyun Moh, Jung Hun Lee, Su Jung Kim, Hyung Sik Kim, Hyo Hyun Seo, Yeon Ja Bae